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Abstract
Background: Neutrophils represent the first line of defence against aggressions. The programmed death of neutrophils is
delayed by pro-inflammatory stimuli to ensure a proper resolution of the inflammation in time and place. The pro-inflammatory
stimuli include granulocyte-macrophage colony-stimulating factor (GM-CSF). Recently, we have demonstrated that although
neutrophils have an identical spontaneous apoptosis in elderly subjects compared to that in young subjects, the GM-CSF-induced
delayed apoptosis is markedly diminished. The present study investigates whether an alteration of the GM-CSF stimulation of
MAPKs play a role in the diminished rescue from apoptosis of PMN of elderly subjects.
Methods: Neutrophils were separated from healthy young and elderly donors satisfying the SENIEUR protocol. Neutrophils
were stimulated with GM-CSF and inhibitors of the MAPKinase pathway. Apoptosis commitment, phosphorylation of signaling
molecules, caspase-3 activities as well as expression of pro- and anti-apoptotic molecules were performed in this study. Data
were analyzed using Student's two-tailed t-test for independent means. Significance was set for p ≤  0.05 unless stated otherwise.
Results: In this paper we present evidence that an alteration in the p42/p44 MAPK activation occurs in PMN of elderly subjects
under GM-CSF stimulation and this plays a role in the decreased delay of apoptosis of PMN in elderly. We also show that p38
MAPK does not play a role in GM-CSF delayed apoptosis in PMN of any age-groups, while it participates to the spontaneous
apoptosis. Our results also show that the alteration of the p42/p44 MAPK activation contributes to the inability of GM-CSF to
decrease the caspase-3 activation in PMN of elderly subjects. Moreover, GM-CSF converts the pro-apoptotic phenotype to an
anti-apoptotic phenotype by modulating the bcl-2 family members Bax and Bcl-xL in PMN of young subjects, while this does not
occur in PMN of elderly. However, this modulation seems MAPK independent.
Conclusion: Our results show that the alteration of p42/p44 MAPK activation contributes to the GM-CSF induced decreased
PMN rescue from apoptosis in elderly subjects. The modulation of MAPK activation in PMN of elderly subjects might help to
restore the functionality of PMN with aging.
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Introduction
Neutrophils represent the first line of defence against
aggressions [1]. They are the first cells to arrive at the site
of the aggression. Neutrophils can directly eliminate the
invading organisms, but most of the time they set the
stage, with other cells of the innate immune system
including macrophages and dendritic cells, to the devel-
opment of the adaptive immune response [2]. The inter-
action between the innate and adaptive immune response
confer to the organism an efficacious defence against
infections, cancers and other aggressions.
Once the neutrophils finished their cleaning and modu-
lating role, they should disappear in an ordered manner
without releasing toxic products from their granules that
eventually harmed the surrounding tissues. If they do not
disappear they would induce a chronic inflammatory
process. Their elimination for the sake of the organism is
occurring through apoptosis [3-5]. Thus, neutrophils are
programmed to die spontaneously in the absence of pro-
inflammatory stimuli [6,7]. This death assures a proper
resolution of the inflammation in time and place.
However, in the presence of pro-inflammatory stimuli
including lipopolysaccharide (LPS), granulocyte-colony-
stimulating factor (G-CSF), granulocyte-macrophage col-
ony-stimulating factor (GM-CSF) neutrophils are able to
postpone their spontaneous propensity for dying and
thus, remain active during more than 72 hours [8]. This
delayed apoptosis confers to neutrophils a highly effica-
cious manner to maintain their activity be able to elimi-
nate properly the aggressors.
It is well accepted that aging is linked to an increase in the
susceptibility to various infections [9]. This is mostly
related to the dysregulation of the immune response [10-
12]. The most studied part is the T-cell induced cellular
immune response, which is considered to be the most
affected by the aging process. However, nowadays it is
also accepted that neutrophils functions are also altered
with aging, even in healthy elderly satisfying the SENIEUR
protocol requirements [13-15]. The most affected func-
tions are the chemotaxis, the free radical productions and
killing. Recently, we have demonstrated that although
neutrophils have an identical spontaneous apoptosis in
elderly subjects compared to that in young subjects, the
GM-CSF induced delayed apoptosis is markedly dimin-
ished [6]. This observation was confirmed by other groups
[17,18]. This decreased GM-CSF induced delay in PMN
apoptosis could have far reaching consequences for PMN
functions and the body defence against infections.
The mechanism of the GM-CSF induced delay of PMN
apoptosis is under intense investigation. It is well known
that GM-CSF induces three distinct signalling pathways in
neutrophils: the Jak/STAT, the MAPK and the PI3K path-
ways [19-21]. Recently, it became evident that the MAPK
and PI3K pathways are participating in the GM-CSF
induced delayed apoptosis of PMN in young subjects
[22]. Recently, we provided evidence that the Jak/STAT
pathway is also contributing to the apoptosis delaying
effect of GM-CSF (manuscript submitted). Furthermore,
these signalling pathways modulate the expression of Bcl-
2 family members as well as that of caspases which play a
determinant role in the fate of cells towards survival or
apoptotic death [23-25].
MAPKinases have been shown to have important roles in
intracellular mechanisms responsible for neutrophils acti-
vation induced by various stimuli, as well as the modula-
tion of their apoptosis [23,26-30]. There exist three
different MAPKs: the extracellular regulated kinase (ERK1/
2 or p42/44), the p38 and the c-Jun terminal kinase
(JNK). Activation of the p42/44 MAPK occurs through
phosphorylation of threonine and tyrosine residues by an
upstream MAPKK (MEK1 and 2) [31]. Both kinases are
known to be weakly auto-phosphorylated on tyrosine.
The activation of p38 is occurring in the same manner
with the MEK3/6 [32]. The p42/p44 MAPK is definitively
involved in the PMN apoptosis rescuing activity of various
agents including LPS, GM-CSF [26-30] while the role of
p38 MAPK remains controversial and seems to depend on
the stimuli used [33-36].
The present study investigates whether an alteration of the
GM-CSF MAPK stimulation play a role in the diminished
rescue from apoptosis of PMN of elderly subjects. In the
present paper we present evidence that an alteration in the
ERK1/2 activation occurs in PMN of elderly subjects under
GM-CSF stimulation and this plays a role in the decreased
delay of apoptosis of PMN in elderly. We also show that
p38 MAPK does not play a role in GM-CSF delayed apop-
tosis in PMN of any age-groups. Our data also show that
the alteration of the p42/p44 MAPK activation results in
the inability of GM-CSF to convert the pro-apoptotic phe-
notype of PMN of elderly subjects to an anti-apoptotic
phenotype by modulating the Bcl-2 family members Bax
and Bcl-xL as well as the caspase-3.
Materials and methods
Reagents and antibodies
Human recombinant GM-CSF was purchased from Calbi-
ochem-Novabiochem (La Jolla, CA). Ethylene glycol-bis
(β -aminoethyl ether)-N, N, N', N'-tetraacetic acid
(EGTA), aprotinin, sodium orthovanadate (Na3VO4),
phenylmethylsulfonyl fluoride (PMSF) and ethylenedi-
aminetetraacetic acid (EDTA) were obtained from Sigma-
Aldrich (St Louis, MO). Leupeptin, chymostatin and pep-
statin were from Boehringer Mannheim (Mannheim, Ger-
many). Iscove's medium was purchased from LifeImmunity & Ageing 2005, 2:6 http://www.immunityageing.com/content/2/1/6
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Technologies (Grand Island, NY). The anti-caspase-3 anti-
body recognizing the p17 fragment of cleaved caspase-3
was a generous gift of Dr. D. Nicholson (Merck Frosst Co.,
Montreal, QC). Anti-phosphotyrosine mAb (4G10), anti-
Bax and anti-Bcl-xL were purchased from Upstate Biotech-
nology Inc. (Lake Placid, NY). Polyclonal anti phospho-
p42/p44 MAPK (Thr202/Tyr204), anti-p42/p44 MAPK,
anti phospho-p38 MAPK (Thr180/Tyr182) and anti-p38
MAPK antibodies were from Santa Cruz (Santa Cruz, CA).
The MEK inhibitor PD98059 and p38 inhibitor SB203580
were from Calbiochem. Cell permeable inhibitors of cas-
pase-3 (Z-DEVD-FMK) and caspase-8 (Z-IETD-FMK) were
purchased from Bio-Rad Laboratories (Mississauga, ON).
Fluorometric caspase-3 substrate (Ac-DEVD-AMC), cas-
pase-3 inhibitor (DEVD-CHO), caspase-8 substrate (Ac-
IETD-AMC) and caspase-8 inhibitor (IETD-CHO) were
from Biosource International. Propidium iodide was from
R&D Systems (Minneapolis, MN). Other reagents were
obtained from Sigma-Aldrich unless stated otherwise.
PMN isolation
Venous blood was collected from 20 young (20–25 years)
and 20 elderly (65–85 years) individuals satisfying the
SENIEUR protocol criteria for immunogerontological
studies, as described [37]. All subjects gave their informed
consent and the protocol was approved by the Hospital
Ethical Committee. Neutrophils were separated by
sequential sedimentation on 2% Dextran T-500 (Amer-
sham Biosciences) in 0.9% sodium chloride, centrifuga-
tion on a Ficoll-Hypaque cushion (specific gravity 1.077,
Amersham Health, Baie d'Urfé, QC) and hypotonic lysis
of erythrocytes, as described [16]. Light microscopy
showed that more than 97% of the cell population was
composed of neutrophils. Cell viability was greater than
95% as assessed by Trypan blue exclusion.
PMN cultures
All experiments were performed using media, serum and
reagents that were free of endotoxins to avoid non-specific
activation of PMN. Purified PMN were suspended (5 × 106
cells/ml) in Iscove's modified Dulbecco's medium supple-
mented with 10% autologous serum, 50 U/ml penicillin
and 25 µg/ml streptomycin and incubated in the presence
or absence (control) of GM-CSF, at a concentration of 20
ng/ml which had been previously determined to induce
maximal PMN response. Other agents used included:
H2O2 (250 µM) and FMLP (10-8 M). These concentrations
were previously determined to induce maximal activation
(16). The cells were incubated for various periods of time
(6 and 18 hours) in polypropylene tubes (Becton Dickin-
son Labware, Lincoln Park, NJ) at 37°C in a humidified
5% CO2-95% air incubator. For some experiments the
MEK1/2 inhibitor, PD98059, and the p38 inhibitor,
SB203580, were used at 30 µM and 10 µM, respectively for
1 hour prior to GM-CSF stimulation, as this concentration
(from 7,5 to 100 µM) and time point (from 30 to 240
min) had been shown to be the most effective to block
these MAPK activities. Stock solution of GM-CSF, H2O2,
FMLP, and PD98059 as well as SB203580 were prepared
in DMSO (final concentration < 0.01% v/v). Preliminary
experiments showed that these concentrations of DMSO
did not increase cell necrosis or the rate of PMN
apoptosis.
Assessment of PMN apoptosis
Apoptosis of PMN was measured by flow cytometry using
FITC-conjugated Annexin V to label externalized phos-
phatidylserine, whereas propidium iodide staining was
used to differentiate apoptosis from necrosis [38]. The
cells were washed in cold PBS and then gently resus-
pended in 0.5 ml of binding buffer (10 mM HEPES, 140
mM NaCl, 2.5 mM CaCl2, pH 7.4) in 12 × 75 mm poly-
styrene tubes. FITC-Annexin V at a saturating concentra-
tion was added to the cell suspension and incubations
were performed in the dark at room temperature for 15
min. Non-specific staining was determined using a Ca2+-
free buffer (10 mM HEPES, 140 mM NaCl, 10 mM EDTA,
pH 7.4). Fluorescence was filtered through a 530/30 nm
band pass to record FITC-Annexin V emission and a 582/
42 nm band pass to detect PI emission. Fluorescence
intensity was measured on a FACScan flow cytometer
(Becton Dickinson, Mountain View, CA) equipped with a
15 mm air cooled 488 nm argon-ion laser. Gating on
physical parameters was used to exclude cell debris and
clumps. A minimum of 10,000 events was analyzed in
each experiment.
Western blot analysis of p42/p44 MAPK, p38 MAPK, Bax, 
Bcl-xL and caspase-3
PMN (107 cells) were cultured in the absence or presence
of GM-CSF (20 ng/ml) and lysed in a buffer containing 20
mM Tris-HCl, pH 7.4, 137 mM NaCl, 10% glycerol, 1%
Nonidet P-40, 2 mM sodium vanadate and 100 mM
sodium fluoride for a 30 min on ice. Cell lysates were cen-
trifuged at 16,000 × g for 15 min and protein concentra-
tion of the supernatants was determined by using the
Bradford protein assay reagent (Bio-Rad). 20 µg of cell
lysates were resolved on a 8% SDS-PAGE, transferred to
Hybond nitrocellulose membranes (Amersham Bio-
sciences) and antigens revealed by probing the membrane
with an anti-phosphotyrosine antibody (4G10) or the rel-
evant antibodies p42/p44MAPK and p38MAPK (phos-
phorylated or not), Bax, Bcl-xL, caspase-3. Membranes
were then washed six times with TBS and incubated with
horseradish peroxidase-conjugated secondary antibody
for 1 h at room temperature. The protein bands were
revealed by densitometry analysis was performed using
the Chemigenius2 Bio Imaging System (Syngene, Freder-
ick, MD) [37].Immunity & Ageing 2005, 2:6 http://www.immunityageing.com/content/2/1/6
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Determination of caspase 3-activity
PMN (5 × 106 cells) were lysed in 100 µl of a 10 mM
potassium phosphate, 1 mM EDTA buffer (pH:7.4) con-
taining 0.5% Triton X-100 supplemented with 2 mM
PMSF, 10 µg/ml leupeptin, 10 µg/ml pepstatin, and 10
mM dithiotreitol for 15 min on ice and spun at 14,000
rpm for 20 min. The lysate (100 µg) was diluted to 1 ml
with ICE buffer (50 mM HEPES, 10% sucrose, 0.1%
CHAPS, pH 7.5) containing 50 µM of the caspase-3 sub-
strate Ac-DEVD-AMC (aspartate-glutamate-valine-aspar-
tate-AMC) [23] and 10 mM freshly prepared dithiotreitol.
Five hundred µl of reaction mixture were diluted with 1.5
ml of ICE buffer and fluorescence (excitation wavelength
400 nm, emission wavelength 505 nm) was read at 1 h
time point. The release of fluorochrome was linear with
time and with the protein concentration used. Standards
containing 0–1500 nM AMC were used to determine the
amount of spontaneous release of fluorochrome. Specifi-
city for caspase-3 activity was demonstrated by using the
caspase-3 inhibitor DEVD-CHO (24). A very low level of
non-specific activity was present, and the effects of the
inhibitor were concentration-dependent. The inhibitor of
caspase-8 IETD-CHO [25] activity assessed by the fluoro-
chrome substrate Ac-IETD-AMC was also included to
insure the specificity of caspase-3 activation.
Statistical analysis
Results are representative of experiments performed with
20 individual donors of each age group. Results are pre-
sented as pooled data from the entire series of experi-
ments (mean ± SD). Data were analyzed using Student's
two-tailed t-test for independent means. Significance was
set for p ≤  0.05 unless stated otherwise.
Results
1. Spontaneous and GM-CSF-induced apoptosis of PMN: 
effect of aging
1.1 Spontaneous apoptosis
In control neutrophils obtained from young subjects, the
mean percentage of apoptotic cells increased steadily from
5 ± 2.7% at 0 hour to 30 ± 6.5% at 18 hours (Fig 1A and
1B, white columns, NS). Similar observations were found
for PMN of elderly subjects where we found that 8 ± 3.0%,
14 ± 3.2% and 44 ± 7.0% were apoptotic, measured by the
expression of Annexin-V at 0 h and 18 h, respectively (Fig-
ure 1A, filled columns, NS). Even if a tendency towards a
higher susceptibility to apoptosis is observed with aging,
this is not significant. It is of note that, the differences in
PMN apoptosis between the basal state and after 18 h of
culture are statistically significant in case of PMN of young
(p < 0.01), as well as of elderly (p < 0.01) subjects.
1.2 Effects of various stimulants on apoptosis of neutrophils cultured 
in vitro
We evaluated, by the expression of Annexin-V using flow
cytometry measurements, the effects of GM-CSF, H2O2,
Dexamethasone (Dex), FMLP and Z-DEVD-FMK, an
inhibitor of caspase-3 (iC3) on the modulation of the
PMN apoptosis for various periods of time. It is well
known that GM-CSF is able to rescue PMN from their
spontaneous apoptosis [6]. As shown in Figure 1A the per-
centage of apoptotic PMN of young subjects treated by
GM-CSF decreased significantly (p < 0.01) after 18 hours
of culture compared to control cultures, starting already at
6 hours (data not shown). In contrast, in PMN of elderly
subjects after GM-CSF treatment a decrease in apoptosis
starting at 6 hours of culture could be also observed, how-
ever this did not become statistically significant at any cul-
ture time (at 18 hours) compared to control cultures
(Figure 1A, filled columns). It is of note that no age-
related differences could be demonstrated for the other
treatments (Figure 1B), except for dexamethasone. In con-
trast to GM-CSF, dexamethasone did not decrease signifi-
cantly the PMN apoptosis in young subjects, but slightly
increased that of elderly subjects, which resulted in a sig-
nificant difference with age (Figure 1B). Finally, we stud-
ied the effect of an inhibitor of caspase-3 on PMN
spontaneous apoptosis. We found that the iC3 signifi-
cantly decreased the spontaneous apoptosis of PMN in
both age-groups (Figure 1A). The caspase-3 inhibitor sig-
nificantly increased the anti-apoptotic effect of GM-CSF as
compared to GM-CSF alone in PMN of young subjects (5
% vs 14 %, respectively; p < 0.05). These results indicate
an efficient synergism at 18 h between the effect of GM-
CSF and of the caspase-3 inhibitor when compared to
spontaneous apoptosis in PMN of young subjects (5 % vs
30 %, respectively; p < 0.05). The synergism seen in the
case of young donors is missing in the case of elderly
donors since GM-CSF is inefficient. Furthermore, these
results indicate that caspase-3 is implicated in the sponta-
neous and GM-CSF modulated apoptosis of PMN of
young and elderly subjects. Altogether, these results sug-
gested that GM-CSF sustained survival is defective with
aging. Thus, the question rose, whether an alteration in
the signal transduction of GM-CSF receptor could contrib-
ute to the altered rescue of PMN of elderly subjects from
apoptosis.
2. Study of the involvement of the MAPK signalling 
pathways in the GM-CSF induced rescue from apoptosis of 
PMN of young and elderly subjects
PMN of young and elderly subjects were stimulated with
GM-CSF during various periods of time (1, 5 and 10 min-
utes, see figure 2 lanes 2, 3, 4), cytosolic proteins were
sized by SDS-PAGE and their pattern of tyrosine phospho-
rylation was assessed by Western blotting with an anti-
phosphotyrosine mAb (4G10). At the basal level, theImmunity & Ageing 2005, 2:6 http://www.immunityageing.com/content/2/1/6
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Measurement of human neutrophils apoptosis with aging by flow cytometry Figure 1
Measurement of human neutrophils apoptosis with aging by flow cytometry. A) GM-CSF-treated (20 ng/ml) or 
untreated neutrophils were cultured during various time periods (from t = 0 to t = 18 h) and stained with Annexin-V conju-
gated to FITC. FACS analyses were performed for fluorescence intensity and data were reported in a time-dependent manner 
for the different experimental conditions and compared to control neutrophils from young (white columns) and elderly donors 
(black columns). Identical experiments were done with Z-DEVD-FMK, inhibitor of caspase-3 activity (iC3) in the presence or 
absence of GM-CSF. Data represent percentage of apoptotic cells from the neutrophil pool. Data were statistically analyzed for 
20 different donors of each group indicated by *p < 0.01. B) The same experiments were done using H2O2 (250 µM), Dexam-
ethasone (10-8 M) and FMLP (10-8 M). Data are from 10 independent experiments with *p < 0.01.Immunity & Ageing 2005, 2:6 http://www.immunityageing.com/content/2/1/6
Page 6 of 16
(page number not for citation purposes)
Protein tyrosine phosphorylation of whole PMN cell lysates after short stimulation with GM-CSF Figure 2
Protein tyrosine phosphorylation of whole PMN cell lysates after short stimulation with GM-CSF Freshly pre-
pared neutrophils were stimulated with GM-CSF for 1 to 10 min and immediately lysed. Lysates were sized on SDS-PAGE fol-
lowed by western-blotting using anti-phosphotyrosine mAbs to reveal protein phosphorylation. The gel shown here is 
representative of 10 independent experiments. Image analyzer was used to measure the amount of phosphorylation and repre-
sented above the gel for each experimental condition in the case of young (white columns) and elderly donors (black columns). 
Similar phosphorylation patterns were obtained from others experiments. A significant increase in total phosphorylation in 
indicated by *p < 0.01, **p < 0.05. A significant difference in basal phosphorylation status of PMN from young and elderly 
donors was found and indicated by ***p < 0.05.Immunity & Ageing 2005, 2:6 http://www.immunityageing.com/content/2/1/6
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protein-tyrosine phosphorylation was significantly
already enhanced in PMN of elderly subjects compared to
that of young subjects (Figure 2A lane 1, p < 0.01). There
is a kinetic increase of the protein-tyrosine phosphoryla-
tion of almost each bands (e.g. p42/44, p110) in PMN of
young subjects after GM-CSF stimulation at 1 min and 5
min (lane 2 and lane 3 respectively, left panel, p < 0.01
compared to basal state) starting to decrease at 10 min
(lane 4 left panel). In contrast, no significant kinetics in
the protein-tyrosine phosphorylation could be observed
in PMN from elderly subjects stimulated with GM-CSF,
probably because of the intense protein-tyrosine phos-
phorylation level at the basal state (Figure 2A lane 1 right
panel). Figure 2B is representing the densitometric scan-
ning of the gels as described in the Materials and Methods
section.
We then focused on p42/p44 MAPK proteins which were
shown to be activated in PMN following GM-CSF receptor
stimulation, as well as by other stimulants [26-30]. It was
already demonstrated that p42/p44 MAPK activation con-
tributed to the decrease of spontaneous apoptosis by GM-
CSF [22]. Therefore, we studied the GM-CSF induced
ERK1/2 activation in PMN in both age-groups. It is of note
that the ERK1/2 tyrosine phosphorylation already detect-
able at basal level did not change during the non-stimu-
lated culture times (1 h, 6 h, 18 h) when compared to the
protein level expression. However, the pre-incubation of
the PMN of young subjects with an inhibitor of MEK1/2,
PD98059 (i-ERK), lead to the complete abrogation of
p42/p44MAPK phosphorylation after 18 hours (Figure 3,
young subjects, left panel). In PMN of young subjects the
protein-tyrosine phosphorylation of p42/p44MAPK
increased by two times after 5 minutes of GM-CSF stimu-
lation and remained thereafter for 18 hours with a slight
decrease at 6 hours (Figure 2, young subjects, right panel).
This increase was mainly due to the p44 components of
the ERK1/2. Once more the PD98059 abrogated the GM-
CSF induced ERK1/2 activation measured by tyrosine
phosphorylation. In contrast, in PMN of elderly we
observed a very strong basal tyrosine phosphorylation
(non-stimulated) compared to that of young subjects (p <
0.01), which decreased thereafter during the non-stimu-
lated incubation (Figure 3, elderly subjects, left panel). We
could not demonstrate any changes in tyrosine phospho-
rylation of p42/p44MAPK during the 6 first hours activa-
tion by GM-CSF in PMN of elderly donors (Figure 3,
elderly subjects, right panel), which even decreased there-
after during the 18 hours of stimulation. The i-ERK could
only partially inhibit the GM-CSF induced ERK1/2 tyro-
sine phosphorylation. Altogether these data indicate that
GM-CSF activates the p42/p44 MAPK by phosphorylation
on tyrosine in a sustained manner during the 18 hours of
culture in PMN of young, while this activation is com-
pletely absent in PMN of elderly subjects.
Next, we assessed the protein tyrosine phosphorylation of
p38 MAPK (Figure 4). The role of p38 in PMN apoptosis
is still controversial [33-36]. There is no evidence that
GM-CSF modulate its activation. However, p38 MAPK
activation has been implicated in the spontaneous apop-
tosis of PMN [33,34]. We present here data that p38
MAPK is tyrosine phosphorylated already at the basal
level, in a significantly (p < 0.01) higher level in PMN of
elderly subjects compared to young subjects (Figure 4A
and 4B). We also show an increase in p38 MAPK phos-
phorylation after 5 min of stimulation by GM-CSF in
PMN of young subjects sustained for 6 hours (Figure 3A,
p < 0.01) and returning to the basal level after 18 hours
when comparing with control protein loading. It is of
note than when the PMN were left untreated for 18 hours
the phosphorylation of p38 on tyrosine was significantly
increased either compared to the basal non-stimulated
status (p < 0.05) or to the 18 hours GM-CSF stimulation
(p < 0.05). There was no tyrosine phosphorylation modu-
lation of p38 in PMN of elderly subjects in response to
GM-CSF stimulation (Figure 3B), which was already very
high at basal level compared to PMN of young subjects (p
< 0.01). These data also suggest that p38 MAPK participate
to the spontaneous apoptosis of PMN in both age-groups,
but did not participate to the GM-CSF delay of apoptosis.
These results further indicate that we assist to an alteration
of the signal transduction in PMN of elderly subjects in
regard to the MAPK pathways.
Then, we tried to link the alteration described previously
in the MAPK pathways in PMN of elderly subjects to the
inability of GM-CSF to rescue them from apoptosis using
the pharmacological inhibitors of p42/p44 and p38
MAPKs. We assessed the spontaneous and GM-CSF
delayed apoptosis of PMN after 18 hours treatment with
PD98059 and SB203580 (Table 1). We found by
Annexin-V/PI staining that apoptosis commitment was
not significantly affected by any of these inhibitors in
PMN of young and elderly subjects (Table 1). When the
PD98059 was applied as pre-treatment to GM-CSF stimu-
lation, it completely abolished the GM-CSF anti-apoptotic
effect in PMN of young subjects, while it had no effect on
GM-CSF of elderly subjects (Table 1). When the
SB203580 was applied as a pre-treatment prior to GM-
CSF stimulation it could not abrogated the GM-CSF apop-
tosis rescuing effect, indicating that p38 is not concerned
by the GM-CSF induced rescue. In PMN of elderly, the
SB203580 pre-incubation had a similar effect than in
PMN of young individuals. Altogether, these data revealed
two main observations, first, the role of the p42/p44
MAPK pathway in PMN survival in contrast to that of p38
MAPK under GM-CSF stimulations and second, the
altered stimulating effect of GM-CSF via the decreased
p42/p44 MAPK phosphorylation due to an increasedImmunity & Ageing 2005, 2:6 http://www.immunityageing.com/content/2/1/6
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basal over-activation contributes to the decreased survival
of PMN of elderly subjects.
3. Role of the Bcl-2 family members Bax and Bcl-xL in GM-
CSF induced rescue of PMN from apoptosis
The Bcl-2 family members are actively participating in the
apoptotic process by being either pro-apoptotic such as
Bax or anti-apoptotic such as Bcl-xL [6]. Their role in the
PMN spontaneous and GM-CSF induced apoptosis was
recently studied [9]. It was shown that the ratio of the pro-
and anti-apoptotic molecules was essential. However, the
presence of Bcl-xL in PMN is still debated [40]. Here, first
we studied how the GM-CSF affected Bax and Bcl-xL
expression after 18 hours of culture in PMN of young and
elderly subjects. We found that in PMN of young subjects
concomitantly to its anti-apoptotic effect the GM-CSF
decrease significantly the expression of Bax (p < 0.01) and
increase the expression of Bcl-xL (Figure 5A and 5C, Figure
6A). In PMN of elderly subjects the GM-CSF was unable to
modulate the expression of Bax, however slightly
increased that of Bcl-xL (Figure 5B and 5D, Figure 6A).
Nevertheless, when the ratio is calculated there is a signif-
icant shift towards survival (Bcl-xL) in PMN of young sub-
jects (Figure 6B), while this is the contrary in PMN of
elderly (increase of Bax) (Figure 6B). When the inhibitors
were used they did not modulate the expression neither of
Activation of p42/p44 MAPK following short and long-time incubation with GM-CSF, effect of aging Figure 3
Activation of p42/p44 MAPK following short and long-time incubation with GM-CSF, effect of aging. Neutrophils 
of young (A) and elderly subjects (B) were stimulated either for 5, 30, 60 min, 6 and 18 hours with GM-CSF alone or pre-
treated with PD98059 (i-ERK) for 1 hours prior to GM-CSF stimulation for 18 hours. Neutrophils were then lysed and ana-
lyzed by western-blotting experiments for p42/p44 MAPK phosphorylation revealing by phospho-anti-p42/p44 MAPK polyclo-
nal Abs. Control loading are shown under each blot for p44. Experiments were performed for 15 different donors of each 
group.Immunity & Ageing 2005, 2:6 http://www.immunityageing.com/content/2/1/6
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Time-dependant activation of p38 MAPK following incubation with GM-CSF, effect of aging Figure 4
Time-dependant activation of p38 MAPK following incubation with GM-CSF, effect of aging. Neutrophils were 
stimulated with GM-CSF from 0 to 18 hours and immediately lysed. Western-blotting experiments of neutrophils of young (A) 
and elderly subjects (B) lysates were conducted by revealing with anti-phospho-p38 MAPK polyclonal Abs. Control loading for 
p38 are shown under each blot. Blots are representative of 15 independent experiments.Immunity & Ageing 2005, 2:6 http://www.immunityageing.com/content/2/1/6
Page 10 of 16
(page number not for citation purposes)
Bax nor of Bcl-xL in any age-groups. These data altogether
indicate that the GM-CSF stimulation create an anti-apop-
totic milieu in the ratio of the Bcl-2 pro-and anti-apop-
totic members, while this is the contrary in PMN of elderly
subjects. Moreover, the MAPK pathways do not seem to
intervene in the modulation of the expression of the Bcl-
2 family members in PMN.
4. Role of caspase-3 in the apoptosis of PMN and its 
modulation by GM-CSF through the MAPK pathway
We have shown that caspase-3 is implicated in the spon-
taneous and GM-CSF modulated apoptosis of PMN of
young and elderly subjects. Caspase-3 is in an uncleaved
form when not activated (procaspase-3). Here we ana-
lyzed by western-blotting experiments the amount of acti-
vated caspase-3 after different experimental conditions
including GM-CSF and inhibitors treatment. We found
that after 18 hours, GM-CSF-treated PMN of young sub-
jects reduced significantly the expression of activated cas-
pase-3 as compared to untreated cells (Figure 7A, young,
lane 2 and 3, p < 0.01). In PMN of elderly subjects the
expression of activated caspase-3 did no change after 18
hours of GM-CSF stimulation, compared to the non-stim-
ulated status (Figure 7A, lane 2 and 3, elderly). When we
applied the inhibitor PD98059, we found a reestablish-
ment of the activated caspase-3 (Figure 7A lane 4, upper
panel) compared to the GM-CSF-treated PMN. The p38
inhibitor, SB203580, did not influence significantly the
activated caspase-3 expression modulation by GM-CSF.
No modulation of the activated caspase-3 expression was
found at any experimental conditions in PMN of elderly
(Figure 7A lane 4, lower panel). These last data indicate a
link between p42/p44MAPK and caspase-3 activation,
however other transduction pathways could also play a
role.
To confirm these results, we measured the caspase-3 activ-
ity by a specific fluorescent substrate (Table 2). In PMN of
young subjects the activity of caspase-3 increased
progressively after 6 hours of culture for reaching a peak
value at 18 hours. For all the incubation times, the cas-
pase-3 activity was significantly higher (p < 0.05) in the
case of elderly donors (Table 2), except at 6 hours. Under
GM-CSF stimulation, caspase-3 activity was significantly
decreased at 6 hours (p < 0.05), 18 hours (p < 0.01) in
PMN of young subjects. It is of note that GM-CSF could
not restore the caspase-3 activity to the level of freshly pre-
pared PMN. In the aged group, in PMN under GM-CSF
treatment no significant decrease could be detected in cas-
pase-3 activity compared to the spontaneous activities of
caspase-3. These data support the fact that GM-CSF is
involved in the modulation of caspase-3 activity which
decreases in PMN of young subjects concomitantly to
their rescue from apoptosis, while PMN of elderly subjects
are unable to decrease caspase-3 activity when GM-CSF is
provided in the milieu.
To further link the MAPK pathways to survival/apoptosis
of PMN we assessed the caspase-3 activity under GM-CSF
stimulation after PD98059 and SB203580 pre-treatment.
Table 1: Neutrophil apoptosis modulation by MAPKinase inhibitors
Treatment Culture time (hours) Annexin-V positive cells (%)
Young Elderly
01 1  ±  2 1 5  ±  3
None 6 11 ± 3 20 ± 3
18 34 ± 6 48 ± 10
GM-CSF 6 11 ± 4 10 ± 5
18 18 ± 3 41 ± 9*
PD98059 18 33 ± 7 45 ± 10
GM-CSF + PD98059 18 40 ± 10 50 ± 15
SB203580 18 43 ± 2 53 ± 5*
GM-CSF + SB203580 18 24 ± 3 33 ± 5*
The cells were cultured for the indicated time in the presence or absence of GM-CSF (20 ng/ml) and the presence or absence of PD98059 (30 µM) 
or SB203580 (10 µM). The percentage of apoptotic was determined by labeling with FITC-conjugated Annexin-V and cell integrity, by Propidium 
iodide (PI) staining. The cells were analyzed by cytofluorimetry. Data are shown as the mean ± SD of five 5 independent experiments. Significant 
differences between young and elderly subjects are indicated by an asterisk (*, p < 0.05 and **, p <0.01).Immunity & Ageing 2005, 2:6 http://www.immunityageing.com/content/2/1/6
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We found that any of these inhibitors alone did not mod-
ulate significantly the caspase-3 activity during the spon-
taneous apoptosis of PMN obtained either from young or
elderly subjects (Table 2). The diminution of caspase-3
activity by GM-CSF in PMN of young subjects (from 908
± 118 to 447 ± 87) could be completely reversed by
PD98059 (from 447 ± 87 to 1126 ± 376), while the
SB203580 could not modulate the effect of GM-CSF on
caspase-3 activity. These inhibitors had no significant
effect on PMN of elderly subjects. These data further con-
firm the essential role of the p42/p44 MAPK pathway in
PMN survival by modulating the caspase-3 activity, while
p38 MAPK is not concerned.
Discussion
Many clinical data indicate that elderly subjects are more
susceptible to infections, particularly to that of the higher
respiratory tracts, more likely caused by atypical organ-
isms as well as to sepsis by gram negative bacteria [9,14].
PMN are the first cells to arrive at the site of invasion and
respond very quickly by the destruction of the aggressor.
Recently, besides the alterations of the adaptive immune
response it was demonstrated that some functions of the
PMN including chemotaxis, killing and production of
bactericidal substances are decreasing with aging [13]
while others remain unchanged such as phagocytosis
[41]. One particular aspect of neutrophils homeostasis is
Expression of bcl-2 family members Bax and Bcl-xL in PMN with aging upon treatment with GM-CSF and PD98059 and  SB203580 for 18 h Figure 5
Expression of bcl-2 family members Bax and Bcl-xL in PMN with aging upon treatment with GM-CSF and 
PD98059 and SB203580 for 18 h. Neutrophils were cultured in presence of GM-CSF alone or in combination with either 
the p42/p44 MAPK inhibitor, PD98059, or the p38 MAPK inhibitor, SB203580, for 18 h. Then, neutrophils were lysed and 
western-blotting experiments were executed to investigate the amount of Bax in young (A) and elderly donors (B). The same 
experiments were conducted for studying Bcl-xl expression in PMN of young (C) and elderly subjects (D). GM-CSF signifi-
cantly decreased the expression of Bax in PMN of young subjects (A, p < 0.01), without any effect in PMN of elderly subjects 
(B). GM-CSF significantly increased the expression of Bcl-xL (p < 0.05) in both age groups (C and D), Blots are representative 
of 15 independent experiments.Immunity & Ageing 2005, 2:6 http://www.immunityageing.com/content/2/1/6
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their propensity to die spontaneously i.e in the absence of
pro-inflammatory stimuli for preserving the organism
from undue destruction or chronic inflammation. In con-
trast, when an inflammatory process increases the level of
pro-inflammatory mediators such as GM-CSF, G-CSF and
LPS, PMN remain functional for 72 hours and die thereaf-
ter by apoptosis.
We have found that in PMN of elderly subjects the GM-
CSF was not able to rescue them from apoptosis as
Densitometric analyses of the expression of bcl-2 family member Bax in PMN with aging upon treatment with GM-CSF and  PD98059 and SB203580 for 18 h as well as the ratio of the expression of Bax/Bcl-xL Figure 6
Densitometric analyses of the expression of bcl-2 family member Bax in PMN with aging upon treatment with 
GM-CSF and PD98059 and SB203580 for 18 h as well as the ratio of the expression of Bax/Bcl-xL. Densitometric 
analysis were performed as described in the Materials and Methods section for the expression of Bax in neutrophils of young 
(white columns) and elderly subjects (black columns) under GM-CSF stimulation (A, *p < 0.01) and after the application of 
inhibitors, PD98059 (i-ERK) and SB203580 (i-p38) (B, p < 0.01). The ratio of Bax to Bcl-xL in PMN of young (white columns) 
and elderly subjects (black columns) under GM-CSF stimulation and modulation by inhibitors is represented (C).Immunity & Ageing 2005, 2:6 http://www.immunityageing.com/content/2/1/6
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Expression of activated caspase-3 in PMN with aging upon treatment with GM-CSF and PD98059 and SB203580 for 18 h Figure 7
Expression of activated caspase-3 in PMN with aging upon treatment with GM-CSF and PD98059 and 
SB203580 for 18 h A) Neutrophils of young (upper panel) and elderly subjects (lower panel) were cultured in presence of 
GM-CSF alone or in combination with either the inhibitor PD98059 (i-ERK) or SB203580 (i-p38), for 18 h. Then, neutrophils 
were lysed and western-blotting experiments were performed to investigate the amount of active caspase-3. With aging no 
changes were found by any agents used (lower panel) while neutrophils from young donors (upper panel) showed significant 
modulation by GM-CSF and PD98059. B, Densitometric analyses were performed as described in the Materials and Methods 
section for the expression of activated caspase-3 in neutrophils of young (white columns) and elderly donors (black columns) 
with *p < 0.01.Immunity & Ageing 2005, 2:6 http://www.immunityageing.com/content/2/1/6
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efficiently as in PMN of young subjects [16]. Here we
present data confirming and extending these results.
Except GM-CSF any other agents used for modulating
PMN apoptosis was found to demonstrate significant age-
related differences. GM-CSF acts as a ligand for its specific
receptor for exercising its anti-apoptotic effect. This means
that if in PMN of elderly the GM-CSF is not able to exert
its anti-apoptotic activity, an alteration in the signalling of
GM-CSF may exist. In fact, in this study we demonstrate
an alteration in the p42/p44 MAPK activation in PMN of
elderly subjects participating in the altered rescue of PMN
from apoptosis. Moreover, we show that p38 MAPK does
not participate in the rescue from apoptosis either in
young or elderly subjects. We present also data that mole-
cules modulating the apoptotic fate of PMN were differen-
tially related to the MAPK pathways. We demonstrate that
the p42/p44 MAPK is not linked to the modulation of the
expression of the Bcl-2 family members, while caspase-3
is partially modulated by this MAPK.
GM-CSF is activating three signalling pathways, Jak/STAT,
MAPK and PI3K [19]. It is now well accepted that in
eosinophils all three pathways are implicated in the GM-
CSF induced rescue from apoptosis [42]. In PMN it is now
also well established that p42/p44 MAPK and PI3K are
implicated in the GM-CSF induced rescue from apoptosis
[22]. We have recently shown that the Jak/STAT signalling
pathway was also involved. We were the first to demon-
strate that GM-CSF is unable to rescue PMN of elderly sub-
jects from apoptosis [16]. This was since confirmed by
other groups. This fact could have far reaching conse-
quences on the susceptibility of elderly to infections. Thus
it is very important to understand why this phenomenon
is occurring in PMN of elderly.
As the p42/p44 MAPK was implicated in PMN of young
subjects in the rescue from apoptosis, we studied whether
this could contribute to the failure of rescue with aging. In
fact, the activation of this MAPK by GM-CSF, as well as by
other substances is strongly related to its anti-apoptotic
effect, showed by the use of specific MEK1/2 inhibitors
[26-30]. Our present data show that p42/p44 MAPK could
not be activated by GM-CSF in the PMN of elderly. This
inability exists either for the short stimulation times or for
longer periods. It is clear from the experiments on PMN of
young subjects that the activation of p42/p44 MAPK is
sustained at least for 18 hours induced by GM-CSF. To
confirm that the p42/p44 MAPK is participating to the res-
cue of PMN from apoptosis we used the inhibitor
PD98059. We found, as others [26-30] that in PMN of
young subjects the use of PD98059 reversed the GM-CSF
inhibitor of apoptosis clearly demonstrating that the ERK/
1/2 is effectively involved in the rescue of apoptosis. In the
case of elderly subjects the lack of p42/p44 MAPK activa-
tion contributes to the altered rescue of PM from apopto-
sis and in fact, the PD98059 could not modulate the PMN
apoptosis.
We also studied whether another member of the MAPK
family namely the p38 MAPK participates to the GM-CSF
Table 2: Modulation of caspase-3 activity in PMN by MAPkinase inhibitors
Treatment Culture time (hours) Caspase-3 activity (arbitrary fluorescence units)
Young Elderly
0 92 ± 20 126 ± 29
None 6 218 ± 38 188 ± 53
18 908 ± 118 1396 ± 207*
GM-CSF 6 113 ± 31 149 ± 42
18 447 ± 87 979 ± 96*
PD98059 18 781 ± 216 1024 ± 413
GM-CSF + PD98059 18 1126 ± 376 1145 ± 387
SB203580 18 1055 ± 267 792 ± 291
GM-CSF + SB203580 18 459 ± 119 900 ± 147 *
PMN isolated from young and elderly donors were maintained in culture for the indicated periods of time. The cells were left untreated, or 
exposed to GM-CSF (20 ng/ml) or a combination of GM-CSF (20 ng/ml) and either in the presence or absence of PD98059 (30 µM) or SB203580 
(10 µM). Caspase-3 activity was measured using a fluorescent substrate. Data are representative of 10 independent experiments. The asterisk (*) 
indicate significant differences (p < 0.05) between the two groups of donors.Immunity & Ageing 2005, 2:6 http://www.immunityageing.com/content/2/1/6
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induced rescue from apoptosis. The role of the p38 MAPK
in PMN apoptosis is controversial [33-36]. Nevertheless,
the consensus seems to exist that its activation participates
in the PMN spontaneous apoptosis. Our present results
confirm this contention in both age-groups. There is a
controversy whether the activation of p38 MAPK partici-
pates in the rescue from apoptosis under various stimula-
tions. In this regard the results of the literature seem to
suggest that p38 MAPK does not participate in the PMN
apoptosis delaying effect of GM-CSF [33-36]. Our present
results indicate that p38 does not contribute to the rescue
from apoptosis neither in PMN of young or elderly
subjects.
Finally to understand how the p42/p44 MAPK can be
implicated in the GM-CSF induced apoptosis of PMN we
studied molecules intervening in the modulation of PMN
apoptosis. These molecules enclosed those of the Bcl-2
family members and the caspases, mainly caspase-3. It
was shown that the Bcl-2 family members are either pro-
apoptotic or anti-apoptotic. In PMN the most important
pro-apoptotic molecule is Bax and the most important
anti-apoptotic ones are the Mcl-1, A1 and Bcl-xL [6]. The
presence of Bcl-xL is still controversial. The ratio between
these molecules determines the fate of PMN. We wanted
to see whether the p42/p44 MAPK activation by GM-CSF
is linked to the expression of the Bax and Bcl-xL molecules
and their ratio. It is known that the p42/p44 MAPK is
linked to the phosphorylation of Bad and freeing in this
way the Bcl-xL, leading to an anti-apoptotic milieu [43].
We found that GM-CSF decreases the expression of Bax
after 18 hours of stimulation, while it increased the
expression of Bcl-XL which gives a ratio in favour of Bcl-
xL, representing the survival. The contrary is occurring in
PMN of elderly where the ratio is in favour of Bax and so
pro-apoptotic. Weinmann et al. [44] showed that GM-CSF
did not modulate the expression of Bcl-xL. Discrepancies
may come from the fact that the concentration of GM-CSF
used was 300 U/ml in their case and only 200 U/ml in our
study. When we treated PMN with higher concentration
we also found a drop in the effect of GM-CSF on Bcl-xL
expression. The use of PD98059 could not reverted the
effect of GM-CSF on the ratio of Bax/Bcl-xL indicating that
the p42/p44 MAPK is not acting directly on these mole-
cules of the Bcl-2 family. This indicates also that the p42/
p44 MAPK is not the only signalling pathway participat-
ing in the GM-CSF induced rescue from apoptosis. As
indicated the Jak/STAT and PI3K pathways are also partic-
ipating. In PMN of elderly as the p42/p44 MAPK could
not be activated by GM-CSF at any time points, it was evi-
dent that no modulation by ERK1/2 inhibitor was found.
The p38 MAPK is not involved in the modulation of these
molecules in PMN at any age-groups.
Furthermore, we were also interested to study the effects
of p42/p44 MAPK on the expression and activity of
another very important executioner protein, the caspase-
3. Caspase-3 was implicated in the spontaneous and GM-
CSF induced rescue of PMN from apoptosis. In fact we
confirmed that GM-CSF could decrease the activated cas-
pase-3 expression and activity in PMN of young subjects,
while has no effect in PMN of elderly. It was also known
that the p42/p44 MAPK is inhibiting the activation of cas-
pase-8 [23]. The use of PD98059 indicated in PMN of
young subjects that the p42/p44 MAPK is implicated in
the GM-CSF induced inhibition of caspase-3, however
this inhibition was not complete. This also indicates that
the GM-CSF has other pathways to modulate the proteins
participating in the executioner phase of apoptosis. In
case of PMN of elderly subjects once again no modulation
of caspase-3 could be demonstrated in any experimental
conditions. For the participation of p38 MAPK in the
modulation of caspase-3 by GM-CSF more work is needed
as the results were not so clear cut.
Altogether, our data demonstrate to our best knowledge
for the first time that the lack of activation of p42/p44
MAPK contribute to the decreased rescue of PMN from
apoptosis in elderly individuals. This decreased activation
results in a pro-apoptotic Bcl-2 family members over-
expression and the activation of caspase-3 in contrast to
PMN of young subjects. We also present data that the acti-
vation of p42/p44 MAPK should be sustained for at least
18 hours to ensure an efficient rescue of PMN from apop-
tosis by GM-CSF. Moreover, our results confirm that the
p38 MAPK participates to the spontaneous apoptosis of
PMN in both age-groups while it did not participate in the
rescue of PMN apoptosis by GM-CSF. Thus, the perspec-
tive of modulation of the p42/p44 MAPK activation in
PMN of elderly subjects may be useful to restore the effec-
tiveness of GM-CSF and contribute to more effective PMN
functionality in elderly. We explore actually what means
can be used to achieve such an increase in p42/p44 MAPK
activation, including the modification of the PMN mem-
brane composition.
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